Results 51 to 60 of about 2,468 (182)

Systemic Thrombolysis in Acute Ischemic Stroke after Dabigatran Etexilate Reversal with Idarucizumab—A Case Report

, 2017
Introduction Idarucizumab is a reversal agent for dabigatran etexilate. By reversing the anticoagulating effect of dabigatran etexilate with idarucizumab (Praxbind), patients presenting with an acute ischemic stroke can now be eligible for thrombolysis ...
Tireli, Derya, Nordling, Mette Maria, Mette Maria Nordling, Jun He, Troels Wienecke, Wienecke, Troels, He, Jun, Derya Tireli   +7 more
core   +1 more source

Practical Recommendations for Anticoagulation in Patients With Atrial Fibrillation

European Journal of Clinical Investigation, Volume 56, Issue 5, May 2026.
Oral anticoagulation (OAC) reduces stroke risk by at least two thirds and mortality by one fourth. The threshold for net clinical benefit of OAC is met when stroke risk exceeds 1%–2% per year. Direct oral anticoagulants (DOACs) are preferred to vitamin K antagonists (VKAs) in most patients, including in the elderly and chronic kidney disease ...
Nicolas Johner, Baris Gencer
wiley   +1 more source

Safety and Efficacy of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Cerebrovascular Ischemic Outcomes in Non‐Valvular Atrial Fibrillation: A Systematic Review and Meta‐Analysis

Clinical Cardiology, Volume 49, Issue 4, April 2026.
Direct Oral Anticoagulants (DOACs) were associated With lower rates of cerebrovascular ischemic events and major bleeding compared With Vitamin K antagonists in non‐valvular atrial fibrillation, With similar mortality. These findings support DOACs as the preferred anticoagulant strategy for stroke prevention in contemporary clinical practice.
Anam Nasir, Naqash Anwar, Abdullah Bin Kamran, Ayesha Muhammad, Ali Haider, Muhammad Mubashar, Fatima Tariq, Mostafa Helou, Besher Shami   +8 more
wiley   +1 more source

Female Sex as a Major Risk Factor for Dabigatran‐Induced Esophagitis in Atrial Fibrillation Ablation

Journal of Arrhythmia, Volume 42, Issue 2, April 2026.
Dabigatran‐induced esophagitis occurred in 18.7% of patients undergoing atrial fibrillation ablation. Female sex was identified as an independent predictor of this complication, highlighting the need for careful periprocedural management and preventive strategies in women.
Daiki Saito, Hidehira Fukaya, Takuya Wada, Jun Oikawa, Sho Ogiso, Yusuke Murayama, Tetsuro Sato, Gen Matsuura, Yuki Arakawa, Shuhei Kobayashi, Hironori Nakamura, Naruya Ishizue, Jun Kishihara, Shinichi Niwano, Satoshi Tanabe, Chika Kusano, Junya Ako   +16 more
wiley   +1 more source

Successful use of idarucizumab for the management of intracranial hemorrhage in an elderly woman receiving dabigatran for stroke prevention in atrial fibrillation: A case report

IHJ Cardiovascular Case Reports, 2018
Non-vitamin K antagonist oral anticoagulants are effective for prevention of stroke in atrial fibrillation (AF) but management of emergency situations in some patients receiving these drugs can be challenging.
Manoj Mashru, Mehul S. Shah, Arun B. Shah, Sonesh kalra, Sandeep Bhapkar   +4 more
doaj   +1 more source

Measuring Direct Oral Anticoagulant (DOAC) Levels: Applications, Limitations, and Future Directions

International Journal of Laboratory Hematology, Volume 48, Issue 2, Page 250-258, April 2026.
ABSTRACT Introduction There are important challenges with the measurement and interpretation of direct oral anticoagulant (DOAC) anticoagulant effect including a lack of therapeutic ranges, inaccuracy of routinely available coagulation assays, lack of established thresholds for clinically significant effect, and uncertainty about how to apply the ...
Siraj Mithoowani, Chee Wee Tan, Deborah M. Siegal   +2 more
wiley   +1 more source

Idarucizumab for the treatment of hemorrhage and dabigatran reversal in patients requiring urgent surgery or procedures.

, 2017
Idarucizumab is a specific antagonist for dabigatran etexilate (DE). The recent market authorization of idarucizumab in Europe and the USA may reassure prescribers of DE, as it can increase the safety of the emergency management of patients taking this ...
Ovidiu Vornicu, Sarah Lessire, Douxfils, Jonathan, François Mullier, Dogné, Jean-Michel, Jonathan Douxfils, Dincq, Anne-Sophie, Anne-Sophie Larock, Vornicu, Ovidiu Ionut, Jean-Michel Dogné, Mullier, François, Larock, Anne-Sophie, Lessire, Sarah, Anne-Sophie Dincq   +13 more
core   +1 more source

Asundexian Versus Apixaban in Patients With Atrial Fibrillation

Health Science Reports, Volume 9, Issue 3, March 2026.
ABSTRACT Background Anticoagulation therapy is central to the prevention of thromboembolic disorders but is limited by bleeding complications associated with traditional agents such as warfarin and direct oral anticoagulants (DOACs). Factor XIa inhibition has emerged as a novel strategy aimed at reducing thrombotic risk while preserving hemostasis ...
Zara Saeed, Syeda Ariba Zehra, Sumyya Tariq, Rocio Pun Zumaran, Mounika Kotte, Zeeshan Hameed, Neeraj Joshi, Pushpa Kumari, Kanta Kumari, Awais Habib, Fawad Talat, Osama Taj, Jahanzeb Malik, Abida Perveen   +13 more
wiley   +1 more source

Idarucizumab, a humanized, monoclonal antibody fragment for immediate reversal of dabigatran

, 2017
Objective: To evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this
Kuyumjian, Yara, Miyares, Marta A., Eaves, Shannon   +2 more
core   +1 more source

Dabigatran Concentrations in an Actively Breastfeeding Mother–Infant Dyad: Extending the Evidence for Oral Thromboprophylaxis Postpartum

American Journal of Hematology, Volume 101, Issue 7, Page 1628-1631, July 2026.
Rasmus W. Green, Aljona Saleh, Pawel Baranczewski   +2 more
wiley   +1 more source